Financing ·
PMV Pharmaceuticals entered into an underwriting agreement with TD Securities for a public offering of common stock…
PMVPPMV Pharmaceuticals, Inc.
PMV Pharmaceuticals entered into an underwriting agreement with TD Securities for a public offering of common stock, pre-funded warrants, and accompanying warrants. The company sold 22,055,000 shares and pre-funded warrants for up to 19,900,000 additional shares, paired with warrants for 41,955,000 shares. Gross proceeds are approximately $50.8 million, yielding net proceeds of about $47.0 million after fees. The offering priced at $1.21 per share and warrant package, with closing expected September 2, 2026. Funds will support late-stage clinical development and commercialization preparation for rezatapopt, a therapy targeting p53 mutations in ovarian cancer. PMV Pharmaceuticals is a precision oncology company developing small molecule therapies.